Stock 600789 SHANDONG LUKANG PHARMACEUTICAL CO.,LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Shandong Lukang Pharmaceutical Co.,Ltd.

Equities

600789

CNE000000P61

Pharmaceuticals

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-04-29 pm EDT 		5-day change 1st Jan Change
7.14 CNY +10.02% Intraday chart for Shandong Lukang Pharmaceutical Co.,Ltd. +20.20% -.--%
Apr. 23 Shandong Lukang Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Mar. 22 Shandong Lukang Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 5,112 6,346 8,248 6,593 6,418 6,361
Enterprise Value (EV) 1 5,654 7,245 9,780 8,687 8,582 8,438
P/E ratio 30.2 x 51.5 x 37.5 x 83.2 x 48.4 x 25.5 x
Yield 0.53% 0.62% 0.59% 0.67% 0.69% 1.26%
Capitalization / Revenue 1.54 x 1.7 x 1.96 x 1.35 x 1.14 x 1.03 x
EV / Revenue 1.7 x 1.94 x 2.33 x 1.78 x 1.53 x 1.37 x
EV / EBITDA 17.8 x 21.9 x 27.6 x 19.8 x 15.8 x 13 x
EV / FCF -6.6 x -15.3 x -13.9 x -20.7 x -222 x -145 x
FCF Yield -15.2% -6.55% -7.18% -4.84% -0.45% -0.69%
Price to Book 1.75 x 2.1 x 2.57 x 2.03 x 1.92 x 1.77 x
Nbr of stocks (in thousands) 880,230 880,230 880,230 880,261 884,036 890,926
Reference price 2 5.808 7.210 9.370 7.490 7.260 7.140
Announcement Date 4/29/19 4/17/20 4/16/21 4/15/22 4/18/23 3/22/24
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 3,330 3,733 4,205 4,891 5,621 6,147
EBITDA 1 317.2 330.4 354.2 438.5 541.8 647
EBIT 1 159.3 143.5 111 135.8 194.1 266.1
Operating Margin 4.78% 3.84% 2.64% 2.78% 3.45% 4.33%
Earnings before Tax (EBT) 1 192.3 148.8 262.2 106.3 150.1 273
Net income 1 161.4 121.3 227.9 82.69 138 246.2
Net margin 4.85% 3.25% 5.42% 1.69% 2.46% 4%
EPS 2 0.1923 0.1400 0.2500 0.0900 0.1500 0.2800
Free Cash Flow 1 -856.8 -474.3 -702.6 -420 -38.63 -58.13
FCF margin -25.73% -12.71% -16.71% -8.59% -0.69% -0.95%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share 2 0.0308 0.0450 0.0550 0.0500 0.0500 0.0900
Announcement Date 4/29/19 4/17/20 4/16/21 4/15/22 4/18/23 3/22/24
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 542 899 1,533 2,094 2,164 2,076
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) 1.709 x 2.72 x 4.326 x 4.774 x 3.993 x 3.209 x
Free Cash Flow 1 -857 -474 -703 -420 -38.6 -58.1
ROE (net income / shareholders' equity) 6.71% 4.13% 7.15% 2.47% 4.13% 7.09%
ROA (Net income/ Total Assets) 1.69% 1.31% 0.97% 1.13% 1.47% 1.9%
Assets 1 9,540 9,234 23,587 7,337 9,416 12,972
Book Value Per Share 2 3.330 3.430 3.650 3.700 3.790 4.030
Cash Flow per Share 2 1.140 1.030 0.7400 0.6300 0.7800 0.8900
Capex 1 855 829 703 487 428 338
Capex / Sales 25.69% 22.2% 16.72% 9.95% 7.62% 5.5%
Announcement Date 4/29/19 4/17/20 4/16/21 4/15/22 4/18/23 3/22/24
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
SHANDONG LUKANG PHARMACEUTICAL CO.,LTD. Stock Shandong Lukang Pharmaceutical Co.,Ltd.
-.--% 884M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+29.68% 681B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+19.34% 556B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.35% 361B
MERCK & CO., INC. Stock Merck & Co., Inc.
+17.65% 325B
ABBVIE INC. Stock AbbVie Inc.
+3.77% 285B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.60% 235B
NOVARTIS AG Stock Novartis AG
+4.30% 199B
ROCHE HOLDING AG Stock Roche Holding AG
-12.27% 189B
PFIZER, INC. Stock Pfizer, Inc.
-3.79% 157B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 600789 Stock
  4. Financials Shandong Lukang Pharmaceutical Co.,Ltd.